RxDoctor Payments Data

Jason Okerlund

Family · Monroe, UTNPI 1649313677

Payments from drug & device makers

$687in general payments, 2019–2025

Across 39 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$306
  • Boehringer Ingelheim$86
  • AstraZeneca$65
  • Merck$35
  • Pfizer$31
  • Sunovion Pharmaceuticals Inc.$28
  • plus $135 from 7 others

What the payments were for

  • Food & beverage$687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$687 in reported general payments places this provider in the 65th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$123,922
Medicare patients
278
Services billed
13,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$80,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$58,904
JardianceEmpagliflozin55$53,491
XareltoRivaroxaban60$47,850
VraylarCariprazine Hcl32$46,379
Soliqua 100-33Insulin Glargine/Lixisenatide19$38,961
OzempicSemaglutide37$34,670
BriviactBrivaracetam19$33,673
TrulicityDulaglutide23$22,282
MounjaroTirzepatide21$22,259
LinzessLinaclotide20$20,923
MyrbetriqMirabegron20$16,119
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,603
OxycontinOxycodone Hcl11$11,305
TradjentaLinagliptin19$10,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$80,75990 claims
AbbVieVraylar, Linzess, Synthroid$306$69,625104 claims
Boehringer IngelheimJardiance, Tradjenta$86$64,44174 claims
GSKTrelegy Ellipta, Breo Ellipta$17$64,37087 claims
Lilly USA, LLCTrulicity, Mounjaro$25$44,54144 claims
Novo NordiskOzempic$18$34,67037 claims
MerckJanuvia, Belsomra$35$14,54836 claims
AstraZenecaBreztri Aerosphere$65$12,60320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,460 family providers in Utah.

Other family in Monroe

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →